Medical Editor: John P. Cunha, DO, FACOEP
What Is Xofluza?
Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of:
- acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours
What Are Side Effects of Xofluza?
Common side effects of Xofluza include:
- diarrhea,
- bronchitis,
- runny or stuffy nose,
- headache, and
- nausea
Dosage for Xofluza
Take a single dose of Xofluza orally within 48 hours of symptom onset with or without food. The dose of Xofluza depends on weight.
What Drugs, Substances, or Supplements Interact with Xofluza?
Xofluza may interact with:
- laxatives,
- antacids, or
- oral supplements that contain calcium, iron, magnesium, selenium, or zinc;
- antiviral drugs, or
- other recent vaccines
Tell your doctor all medications and supplements you use and all vaccines you recently received.
Xofluza During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Xofluza; it is unknown how it would affect a fetus. It is unknown if Xofluza passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Xofluza (baloxavir marboxil) Tablets, for Oral Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
QUESTION
Which illness is known as a viral upper respiratory tract infection? See Answer3 pharmacies near 20147 have coupons for Xofluza (Brand Names:Xofluza for 2 x 20MG)
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Common side effects may include:
- cough, chest congestion;
- nausea, diarrhea;
- headache; or
- runny or stuffy nose.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Xofluza (Baloxavir Marboxil)
SLIDESHOW
How to Get Rid of a Cold: Natural Remedies See SlideshowSIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The overall safety profile of XOFLUZA is based on data from 1,943 subjects 12 years of age and older in 4 controlled clinical trials who received XOFLUZA [see Clinical Studies].
Treatment Of Acute Uncomplicated Influenza
Adult And Adolescent Subjects
The safety of XOFLUZA in adult and adolescent subjects is based on data from 3 placebo-controlled trials in which a total of 1,640 subjects received XOFLUZA: 1,334 (81%) subjects were 18 to 64 years of age, 209 (13%) subjects were adults 65 years of age or older, and 97 (6%) subjects were adolescents 12 to 17 years of age. These trials included otherwise healthy adults and adolescents (N=910) and subjects at high risk of developing complications associated with influenza (N=730). Of these, 1,440 subjects received XOFLUZA at the recommended dose [see Clinical Studies]. Trial 1 was a phase 2 dose-finding placebo-controlled trial where otherwise healthy adult subjects 20 to 64 years of age received single oral dose of XOFLUZA or placebo. Trial 2 was a placebo- and active-controlled trial in otherwise healthy adults and adolescents 12 to 64 years of age; subjects received weight-based XOFLUZA or placebo as a single oral dose on Day 1 or oseltamivir twice a day for 5 days. Trial 3 was a randomized, double-blind, placebo- and active controlled trial where adults and adolescents at high risk of influenza complications 12 years of age and older received either XOFLUZA, placebo or oseltamivir.
Table 3 displays the most common adverse events (regardless of causality assessment) reported in at least 1% of adult and adolescent subjects who received XOFLUZA at the recommended dose in Trials 1, 2, and 3.
Table 3 : Incidence of Adverse Events Occurring in at Least 1% of Adult and Adolescent Subjects Receiving XOFLUZA in the Acute Uncomplicated Influenza Trials 1, 2, and 3
| Adverse Event | XOFLUZA (N=1,440) |
Placebo (N=1,136) |
| Diarrhea | 3% | 4% |
| Bronchitis | 3% | 4% |
| Nausea | 2% | 3% |
| Sinusitis | 2% | 3% |
| Headache | 1% | 1% |
Post-Exposure Prophylaxis Of Influenza
The safety of XOFLUZA in adult and adolescent subjects is based on data from one placebo-controlled clinical trial in which 374 subjects, of which 303 were adult and adolescent subjects ≥ 12 years, received XOFLUZA: eight (3%) subjects were adults 65 years of age or older, and 12 (4%) subjects were adolescents 12 to 17 years of age. The most frequently reported AE in the total study population was nasopharyngitis which occurred in 6% of subjects who received XOFLUZA and 7% on placebo [see Clinical Studies].
Postmarketing Experience
The following adverse reactions have been identified during postmarketing use of XOFLUZA. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to XOFLUZA exposure.
Immune System Disorders: Anaphylactic reactions, anaphylactic shock, anaphylactoid reactions, hypersensitivity reactions, angioedema (swelling of face, eyelids, tongue and lips)
Skin and Subcutaneous Tissue Disorders: Rash, urticaria, erythema multiforme
Gastrointestinal Disorders: Vomiting, hematochezia, melena, colitis
Psychiatric Disorders: Delirium, abnormal behavior, hallucinations
DRUG INTERACTIONS
Effect Of Other Drugs On XOFLUZA
Baloxavir may form a chelate with polyvalent cations such as calcium, aluminum, or magnesium. Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir [see CLINICAL PHARMACOLOGY], which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).
Vaccines
The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.
Read the entire FDA prescribing information for Xofluza (Baloxavir Marboxil)
© Xofluza Patient Information is supplied by Cerner Multum, Inc. and Xofluza Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
Health Solutions From Our Sponsors